<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158267">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02150993</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12294 FIT-2</org_study_id>
    <nct_id>NCT02150993</nct_id>
  </id_info>
  <brief_title>First-Line Treatment for HIV-2</brief_title>
  <acronym>FIT-2</acronym>
  <official_title>A Randomized, Non-comparative, Phase IIb, Unblinded Trial, Evaluating the Efficacy and Safety of Tenofovir-emtricitabine or Lamivudine Plus Zidovudine, Lopinavir/Ritonavir, or Raltegravir, Among ARV-naïve HIV-2 Infected Adult Patients, in West Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <authority>Burkina Faso: Ministry of Health</authority>
    <authority>Burkina Faso: Ministère de la Recherche Scientifique et de l'Innovation</authority>
    <authority>Burkina Faso: Comité d'Ethique pour la Recherche en Santé</authority>
    <authority>Cote d'Ivoire: Ministère de la Santé et de la Lutte contre le SIDA</authority>
    <authority>Cote d'Ivoire: Comité National d'Ethique et de la Recherche</authority>
    <authority>Senegal: Ministere de la Sante et de l'Action Sociale</authority>
    <authority>Senegal: Comité National d'Ethique pour la Recherche en Santé</authority>
    <authority>Guinee Conakry:  Ministère de la Santé et de l'Hygiène Publique (MSHP)</authority>
    <authority>Guinee Conakry: Comité national d'éthique pour la recherche en santé (CNERS)</authority>
    <authority>Togo : Comité de bioéthique pour la recherche en santé ( CBRS)</authority>
    <authority>Togo : ministère de la santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FIT-2 is a multi-country, phase IIb, randomized, non-comparative study, carried out in West
      Africa (Côte d'Ivoire, Burkina Faso, Senegal, Togo, Guinea).

      ARV-naïve HIV-2 infected adult patients will be recruited and followed during 96 weeks.

      The objective is to evaluate the efficacy and safety of 3 first-line treatments in HIV-2
      infected adult patients, in West Africa. A treatment will be considered as effective if more
      than 55% of patients in that arm attain &quot;global success&quot; at 96 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective

      To determine in treatment-naïve HIV-2 infected patients, with CD4 counts between 200 and 600
      cells/mm3  or with HIV-2 RNA viral loads &gt;50copies/ml and CD4 counts above 200 cells/mm3,
      which of the following three regimens of first line treatment, Tenofovir (TDF),
      Emtricitabine or lamivudine (FTC or 3TC) plus Zidovudine (ZDV); TDF-FTC (3TC) plus
      Lopinavir/ritonavir (LPV / r); or TDF-FTC (3TC) plus raltegravir (RAL), will result in an
      &quot;global success&quot; rate of &gt; 55% at week 96.

      Number of participants : 210

      Main outcome :

      The proportion of patients with &quot;global success&quot; at W96, defined by survival with a plasma
      HIV-2 RNA viral load of ≤50 copies/ml and the non-occurrence of AIDS classified events
      (excluding tuberculosis) and a delta of CD4 depending on the initial CD4 count (CD4 delta&gt;
      +100cells/mm3 for initial CD4s between 201 and 500 cells/mm3 or delta&gt; 50 cells/mm3 for
      initial CD4s &gt; +500 cells/mm3)

      Inclusion criteria:

        -  Infection by HIV-2 only;

        -  Age &gt; or = 18 years;

        -  Naïve for antiretroviral therapy (including antiretroviral treatment in the context of
           PMTCT)

        -  CD4 &gt;200/mm3 and ≤600/mm3 irrespective of plasma HIV-2 RNA viral load, OR HIV-2 RNA
           viral load plasma &gt; 50 copies/ml if the CD4 count is &gt;200 cells/mm3

        -  Resident of the city where the study is held or of city suburbs to facilitate
           participation

        -  Signed informed consent
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The &quot;overall success&quot;</measure>
    <time_frame>96 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of patients with &quot;global success&quot; at W96, defined by survival with a plasma HIV-2 RNA viral load of ≤50 copies/ml and the non-occurrence of AIDS classified events (excluding tuberculosis) and a delta of CD4 depending on the initial CD4 count (CD4 delta&gt; +100cells/mm3 for initial CD4s between 201 and 500 cells/mm3 or delta&gt; 50 cells/mm3 for initial CD4s &gt; +500 cells/mm3)
A treatment is considered to be effective if the &quot;global success&quot; is &gt; 55 % at 96 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic failure</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of patients in &quot;treatment failure&quot; defined by :
death or
a delta CD4 ≤0 cells/mm3 or
a plasma HIV-2 RNA viral load of &gt;50 copies/ml or
the occurrence of an AIDS defining event (excluding tuberculosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic failure</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of patients in &quot;treatment failure&quot; defined by :
death or
a delta CD4 ≤0 cells/mm3 between  or
a plasma HIV-2 RNA viral load of &gt;50 copies/ml or
the occurrence of an AIDS defining event (excluding tuberculosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and type of severe clinical or biological severe adverse events (grade 3 or 4 on the ANRS grading table) per arm</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical progression</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The incidence of severe morbidity, defined as: AIDS morbidity, non-AIDS cancer, severe non-AIDS bacterial disease, or any disease leading to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evolution of CD4 counts</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evolution of the absolute and percentage CD4 counts during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evolution of plasma HIV-2 RNA load</measure>
    <time_frame>between at W0 and W96</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evolution of the plasma viral load during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The observance of antiretroviral treatment</measure>
    <time_frame>between W0 and W96</time_frame>
    <safety_issue>No</safety_issue>
    <description>To describe the antiretroviral possession ratio and assessment of compliance by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The resistance mutations profile</measure>
    <time_frame>Weeks 96</time_frame>
    <safety_issue>No</safety_issue>
    <description>Description of new resistance mutations profiles in cases of treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evolution of the HIV-2 DNA titers in PBMC</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <safety_issue>No</safety_issue>
    <description>To describe the evolution the HIV-2 DNA titers in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of treatment switches and discontinuations</measure>
    <time_frame>between Week 0 and Week 96</time_frame>
    <safety_issue>No</safety_issue>
    <description>The frequency of modifications and discontinuations of treatment per arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To model the long-term survival and cost-effectiveness ratio</measure>
    <time_frame>Weeks 96</time_frame>
    <safety_issue>No</safety_issue>
    <description>The probability of survival and the incremental cost-effectiveness of these three treatment regimens</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>HIV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Arm A : TDF + FTC (or 3TC) + ZDV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir + Emtricitabine or Lamivudine + Zidovudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF+FTC (or 3TC) +LPV/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C : TDF +FTC (or 3TC) + RAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir + Emtricitabine or Lamivudine + Raltegravir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + Emtricitabine or Lamivudine + Zidovudine</intervention_name>
    <description>TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)</description>
    <arm_group_label>Arm A : TDF + FTC (or 3TC) + ZDV</arm_group_label>
    <other_name>TDF+FTC (or 3TC) + ZDV</other_name>
    <other_name>TDF+FTC (or 3TC) + AZT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir</intervention_name>
    <description>TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)</description>
    <arm_group_label>TDF+FTC (or 3TC) +LPV/r</arm_group_label>
    <other_name>TDF +FTC (or 3TC) +LPV/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + Emtricitabine or Lamivudine + Raltegravir</intervention_name>
    <description>TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)</description>
    <arm_group_label>Arm C : TDF +FTC (or 3TC) + RAL</arm_group_label>
    <other_name>TDF +FTC (or 3TC) + RAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infection by HIV-2 only;

          -  Age &gt; 18 years;

          -  Naïve for antiretroviral therapy (including antiretroviral treatment in the context
             of PMTCT)

          -  CD4 &gt;200/mm3 and ≤600/mm3 irrespective of plasma HIV-2 RNA viral load, OR HIV-2 RNA
             viral load plasma &gt; 50 copies/ml if the CD4 count is &gt;200 cells/mm3

          -  Resident of the city where the study is held or of city suburbs to facilitate
             participation

          -  Signed informed consent document

        Exclusion Criteria:

          -  Current participation in any other clinical trial

          -  Presence of opportunistic non-stabilized infections, of any serious or progressive
             disease, or of any clinical signs consistent with severe disease whose diagnosis is
             not yet confirmed, such as fever, weight loss, diarrhea or cough not yet explained
             (non-exhaustive list).

          -  All pathology that leads in daily life to prefer one or the other of the three
             therapeutic regimens for medical reasons or to change the dosages specified in the
             test. This includes (but not limited to):

          -  Hemoglobin ≤ 8 g / L

          -  Neutrophil count &lt;500 cells/mm3

          -  Renal impairment with creatinine clearance &lt;50mL/mn

          -  Decompensated heart failure

          -  Hepatic failure Severe (TP&lt;50% or cytolysis severe (ALAT&gt; 3x ULN)

          -  Active TB during treatment with rifampicin

          -  Taking drugs that interact with the drugs of the clinical trial  (as specified in the
             SPC)

          -  Pregnancy, breastfeeding or planning to become pregnant during study follow-up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge P. Eholié, MD, MSc, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service des Maladies Infectieuses et Tropicales,  CHU de Treichville, Abidjan, Côte d'Ivoire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Françoise P. Brun-Vézinet, MD, MSc, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratoire de virologie, Hôpital Bichat-Claude Bernard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Géraldine Colin, DPharm</last_name>
    <phone>+22521755960</phone>
    <email>geraldine.colin11@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier Anglaret, MD, PHD</last_name>
    <phone>+22521755960</phone>
    <email>Xavier.Anglaret@isped.u-bordeaux2.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Sourô Sanou</name>
      <address>
        <city>Bobo-Dioulasso</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrien B Sawadogo, MD</last_name>
      <phone>+22620985255</phone>
      <email>sawadogoadrien@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jacques Zougrana, MD</last_name>
      <phone>+22620983758</phone>
      <email>zojacques@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jacques Zoungrana, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Yalgado Ouedraogo</name>
      <address>
        <city>Ouagadougou</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Youssef Joseph Drabo, Pr. MD</last_name>
      <phone>+22650311656</phone>
      <email>yjdrabo@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ismael Diallo, MD</last_name>
      <phone>+22670249814</phone>
      <email>illah_diallo@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Isamel Diallo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Prise en Charge et de Formation (CePReF), Association ACONDA</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eugène Messou, MD, PhD</last_name>
      <phone>+22523462551</phone>
      <email>messou_eugene@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Médical du Suivi des Donneurs de Sang (Blood Bank Medical Centre)</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Kla Minga, MD, PhD</last_name>
      <phone>+225 21 35 52 78</phone>
      <email>minga.albert@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales (SMIT)</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Bissagnene, MD, Pr</last_name>
      <phone>+22521755960</phone>
      <email>bissagnene@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Eboumou Gole, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIRBA</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henry Chenal, MD</last_name>
      <email>chenalhenri@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Denise Hawerlander, MD</last_name>
      <phone>+225 07 67 25 59</phone>
      <email>hawer_d@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Denise Hawerlander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHNU Fann</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moussa Seydi, MD, Pr</last_name>
      <phone>+221338231327</phone>
      <email>seydi_moussa@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nogaye Gaye</last_name>
      <phone>+221338698193</phone>
      <email>nogayegaye@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital du district de Ziguinchor</name>
      <address>
        <city>Ziguinchor</city>
        <country>Senegal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noël Magloire Manga, MD</last_name>
      <phone>+221338647553</phone>
      <email>noelmagloiremanga@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Sylvanus-Olympio</name>
      <address>
        <city>Lomé</city>
        <country>Togo</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patassi Akouda, MD</last_name>
      <phone>+228 90 98 17 74</phone>
      <email>patassi40@yahoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
    <country>Côte D'Ivoire</country>
    <country>Senegal</country>
    <country>Togo</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>sponsor site</description>
  </link>
  <link>
    <url>http://www.mereva.net/</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Africa</keyword>
  <keyword>Antiretroviral Treatment</keyword>
  <keyword>HIV-2</keyword>
  <keyword>firsts line ART</keyword>
  <keyword>Adults</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
